Droxidopa (hydrochloride)

Droxidopa (L-DOPS) hydrochloride is a potent, orally active norepinephrine precursor. Droxidopa hydrochloride increases standing blood pressure, ameliorates symptoms of orthostatic hypotension and improves standing ability. Droxidopa hydrochloride has the potential for the research of neurogenic orthostatic hypotension (nOH) and alternative ADHD (attention deficit hyperactivity disorder) [1][2][3][4].

Product Specifications

CAS Number

[1260173-94-1]

Product Name Alternative

L-DOPS (hydrochloride) ; DOPS (hydrochloride) ; SM5688 (hydrochloride)

UNSPSC

12352005

Target

Adrenergic Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/droxidopa-hydrochloride.html

Solubility

10 mM in DMSO

Smiles

OC1=C(O)C=CC([C@@H](O)[C@@H](C(O)=O)N)=C1.Cl

Molecular Formula

C9H12ClNO5

Molecular Weight

249.65

References & Citations

[1]Horacio Kaufmann, et al. Droxidopa for neurogenic orthostatic hypotension. Neurology, 2014; 83 (4) .|[2]Dela Peña I, et al. Droxidopa alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats. Eur J Pharmacol. 2021 Feb 5;892:173826.|[3]Cao LF, et al. Restoring Spinal Noradrenergic Inhibitory Tone Attenuates Pain Hypersensitivity in a Rat Model of Parkinson's Disease. Neural Plast. 2016;2016:6383240. |[4]Kaufmann H. L-dihydroxyphenylserine (Droxidopa) : a new therapy for neurogenic orthostatic hypotension: the US experience. Clin Auton Res. 2008 Mar;18 Suppl 1:19-24.